We have located links that may give you full text access.
Comparative Study
Journal Article
Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine.
International Urology and Nephrology 2015 January
BACKGROUND: We have previously reported the results of mizoribine (MZR) treatment for elderly patients with membranous nephropathy (MN). Here, we retrospectively compared these patients with those who had been initially treated with prednisolone (PSL) alone.
METHODS: The subjects were patients with MN aged ≥65 years who were examined between April 2007 and September 2010 and followed for at least 1 year.
RESULTS: The median period until the start of treatment in the MZR group (MZR-G) was 60 days. The urinary protein level at the start of MZR treatment was 3.89±2.3 g/gCr. Urinary protein in the group not treated with MZR (N-MZR-G) was 1.0±1.1 g/gCr, showing a tendency to improve in patients with nephrotic syndrome relative to the MZR-G (p=0.055). The PSL dose in the MZR-G versus N-MZR-G at 1 year was 5.7±3.0 versus 6.25±2.5 mg/day, the urinary protein level was 0.19±0.2 versus 0.13±0.1 g/gCr, and the remission rate was 80 versus 75%. In the MZR-G, the total PSL dose at 1 year after the start of MZR treatment was 5,058±1,904 versus 6,649±875 mg in the N-MZR-G. Adverse events occurred in 3/5 patients (60%) in the MZR-G and in 3/4 patients (75%) in the N-MZR-G.
CONCLUSION: Elderly patients with MN who respond poorly to PSL treatment may be treated successfully with MZR.
METHODS: The subjects were patients with MN aged ≥65 years who were examined between April 2007 and September 2010 and followed for at least 1 year.
RESULTS: The median period until the start of treatment in the MZR group (MZR-G) was 60 days. The urinary protein level at the start of MZR treatment was 3.89±2.3 g/gCr. Urinary protein in the group not treated with MZR (N-MZR-G) was 1.0±1.1 g/gCr, showing a tendency to improve in patients with nephrotic syndrome relative to the MZR-G (p=0.055). The PSL dose in the MZR-G versus N-MZR-G at 1 year was 5.7±3.0 versus 6.25±2.5 mg/day, the urinary protein level was 0.19±0.2 versus 0.13±0.1 g/gCr, and the remission rate was 80 versus 75%. In the MZR-G, the total PSL dose at 1 year after the start of MZR treatment was 5,058±1,904 versus 6,649±875 mg in the N-MZR-G. Adverse events occurred in 3/5 patients (60%) in the MZR-G and in 3/4 patients (75%) in the N-MZR-G.
CONCLUSION: Elderly patients with MN who respond poorly to PSL treatment may be treated successfully with MZR.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app